Vascodagama Online Journal

Hypoxic Ischemic Encephalopathy Market to Exhibit Moderate Growth Rate During the Forecast Period (2022-2032), Investigates DelveInsight | Key Companies – Takeda Pharma, Bayer AG, Novartis AG, Biogen

 Breaking News
  • No posts were found

Hypoxic Ischemic Encephalopathy Market to Exhibit Moderate Growth Rate During the Forecast Period (2022-2032), Investigates DelveInsight | Key Companies – Takeda Pharma, Bayer AG, Novartis AG, Biogen

April 11
21:28 2023
Hypoxic Ischemic Encephalopathy Market to Exhibit Moderate Growth Rate During the Forecast Period (2022-2032), Investigates DelveInsight | Key Companies - Takeda Pharma, Bayer AG, Novartis AG, Biogen
DelveInsight’s “Hypoxic Ischemic Encephalopathy Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Hypoxic Ischemic Encephalopathy.

DelveInsight’s “Hypoxic Ischemic Encephalopathy Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Hypoxic Ischemic Encephalopathy, historical and forecasted epidemiology as well as the Hypoxic Ischemic Encephalopathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

To Know in detail about the Hypoxic Ischemic Encephalopathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hypoxic Ischemic Encephalopathy Market Forecast

 

Some of the key facts of the Hypoxic Ischemic Encephalopathy Market Report: 

  • The Hypoxic Ischemic Encephalopathy market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • As per the HIE Help Center, Neonatal HIE is estimated to occur in about 1.5 per 1,000 live births. Among infants with moderate HIE, 10-20% develop minor neurological conditions, and 30-50% develop more serious complications. For infants with severe HIE, there is a 25-50% mortality rate. Deaths most often occur in the first few days after birth. Of babies that survive, roughly 80% develop serious complications
  • In a population based study from January 2010 to December 2017 by Hage et al. (2021), 5201 babies with a diagnosis of HIE received TH or died; annual numbers increased over the study period
  • Neonatal encephalopathy due to birth asphyxia and trauma is the second leading cause of death in the first month of child’s life
  • According to a trend analysis by Shipley et al. (2021), it was found that among 407,462 infants admitted for neonatal care, 12 ,195 were diagnosed with HIE. 8,166 infants ≥36 weeks GA had moderate/severe Hypoxic Ischemic Encephalopathy, 62.1% (n=5069) underwent TH and mortality was 9.3% (n=762)
  • Key Hypoxic Ischemic Encephalopathy Companies: Takeda Pharma, Bayer AG, Novartis AG, Biogen, AstraZeneca, Eisai Co. Ltd., Johnson & Johnson, Pfizer, Inc., Sanofi, Teva Pharmaceuticals Industries Ltd., Allergan, Merz Pharma, , Inc., F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, AbbVie Inc., Lily.,  VTV Therapeutics, H. Lundbeck A/S, ReAlta Life Sciences, Hope Biosciences, GW Pharmaceuticals, TauRx Pharmaceuticals Ltd, DAIICHI SANKYO COMPANY, LIMITED, and others
  • Key Hypoxic Ischemic Encephalopathy Therapies: RLS-0071, HB-adMSCs, Additional cannabinoids, and others
  • The Hypoxic Ischemic Encephalopathy epidemiology based on gender analyzed that male infants are more vulnerable to neonatal Hypoxic Ischemic Encephalopathy and suffer more long-term deficits than female
  • The Hypoxic Ischemic Encephalopathy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hypoxic Ischemic Encephalopathy pipeline products will significantly revolutionize the Hypoxic Ischemic Encephalopathy market dynamics.

 

Hypoxic Ischemic Encephalopathy Overview

Hypoxic-ischemic encephalopathy (HIE) is a serious and life-threatening type of newborn brain damage (brain dysfunction) that occurs when the brain doesn’t receive enough oxygen and blood flow for a period of time. As the name suggests, Hypoxic means, not enough oxygen; ischemic means not enough blood flow; and encephalopathy means brain disorder.

 

Get a Free sample for the Hypoxic Ischemic Encephalopathy Market Report – 

https://www.delveinsight.com/sample-request/hypoxic-ischemic-encephalopathy-market

 

Hypoxic Ischemic Encephalopathy Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Hypoxic Ischemic Encephalopathy Epidemiology Segmentation:

The Hypoxic Ischemic Encephalopathy market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Hypoxic Ischemic Encephalopathy
  • Prevalent Cases of Hypoxic Ischemic Encephalopathy by severity
  • Gender-specific Prevalence of Hypoxic Ischemic Encephalopathy
  • Diagnosed Cases of Episodic and Chronic Hypoxic Ischemic Encephalopathy

 

Download the report to understand which factors are driving Hypoxic Ischemic Encephalopathy epidemiology trends @ Hypoxic Ischemic Encephalopathy Epidemiology Forecast

 

Hypoxic Ischemic Encephalopathy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hypoxic Ischemic Encephalopathy market or expected to get launched during the study period. The analysis covers Hypoxic Ischemic Encephalopathy market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Hypoxic Ischemic Encephalopathy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Hypoxic Ischemic Encephalopathy Therapies and Key Companies

  • RLS-0071: ReAlta Life Sciences
  • HB-adMSCs: Hope Biosciences
  • Additional cannabinoids: GW Pharmaceuticals

 

Discover more about therapies set to grab major Hypoxic Ischemic Encephalopathy market share @ Hypoxic Ischemic Encephalopathy Treatment Market

 

Hypoxic Ischemic Encephalopathy Market Strengths

  • This condition has high unmet needs in regards to the available therapy option. This creates a spaces for the pharmaceutical companies to launch their products with exclusivity and premium pricing

 

Hypoxic Ischemic Encephalopathy Market Opportunities

  • With the increasing global population, the incidence of Hypoxic ischemic encephalopathy has also surged, leading to increased opportunities for research and development

 

Scope of the Hypoxic Ischemic Encephalopathy Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Hypoxic Ischemic Encephalopathy Companies: Takeda Pharma, Bayer AG, Novartis AG, Biogen, AstraZeneca, Eisai Co. Ltd., Johnson & Johnson, Pfizer, Inc., Sanofi, Teva Pharmaceuticals Industries Ltd., Allergan, Merz Pharma, , Inc., F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, AbbVie Inc., Lily.,  VTV Therapeutics, H. Lundbeck A/S, ReAlta Life Sciences, Hope Biosciences, GW Pharmaceuticals, TauRx Pharmaceuticals Ltd, DAIICHI SANKYO COMPANY, LIMITED, and others
  • Key Hypoxic Ischemic Encephalopathy Therapies: RLS-0071, HB-adMSCs, Additional cannabinoids, and others
  • Hypoxic Ischemic Encephalopathy Therapeutic Assessment: Hypoxic Ischemic Encephalopathy current marketed and Hypoxic Ischemic Encephalopathy emerging therapies
  • Hypoxic Ischemic Encephalopathy Market Dynamics: Hypoxic Ischemic Encephalopathy market drivers and Hypoxic Ischemic Encephalopathy market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Hypoxic Ischemic Encephalopathy Unmet Needs, KOL’s views, Analyst’s views, Hypoxic Ischemic Encephalopathy Market Access and Reimbursement 

 

To know more about Hypoxic Ischemic Encephalopathy companies working in the treatment market, visit @ Hypoxic Ischemic Encephalopathy Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Hypoxic Ischemic Encephalopathy Market Report Introduction

2. Executive Summary for Hypoxic Ischemic Encephalopathy

3. SWOT analysis of Hypoxic Ischemic Encephalopathy

4. Hypoxic Ischemic Encephalopathy Patient Share (%) Overview at a Glance

5. Hypoxic Ischemic Encephalopathy Market Overview at a Glance

6. Hypoxic Ischemic Encephalopathy Disease Background and Overview

7. Hypoxic Ischemic Encephalopathy Epidemiology and Patient Population

8. Country-Specific Patient Population of Hypoxic Ischemic Encephalopathy 

9. Hypoxic Ischemic Encephalopathy Current Treatment and Medical Practices

10. Hypoxic Ischemic Encephalopathy Unmet Needs

11. Hypoxic Ischemic Encephalopathy Emerging Therapies

12. Hypoxic Ischemic Encephalopathy Market Outlook

13. Country-Wise Hypoxic Ischemic Encephalopathy Market Analysis (2019–2032)

14. Hypoxic Ischemic Encephalopathy Market Access and Reimbursement of Therapies

15. Hypoxic Ischemic Encephalopathy Market Drivers

16. Hypoxic Ischemic Encephalopathy Market Barriers

17.  Hypoxic Ischemic Encephalopathy Appendix

18. Hypoxic Ischemic Encephalopathy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

Categories